A randomized, double-blind placebo-controlled phase II study of FOLFOX with or without GDC-0449 (vismodegib) in patients with advanced gastric and gastroesophageal junction carcinoma (NCI 8376).
D. J. Cohen
No relevant relationships to disclose
L. Liebes
No relevant relationships to disclose
R. Xu
No relevant relationships to disclose
N. Takebe
No relevant relationships to disclose
J. A. Sparano
Consultant or Advisory Role - Genentech